Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state

BMC Infectious Diseases

Liem Thanh Nguyen²  Son Hong Pham²  Hung Viet Pham¹  Thuy Thi Bich Phung²  Thanh Thi Mai Doan³ 

[1] Vietnam National Hospital of Pediatrics, Hanoi, Vietnam;Research Institute for Child Health, Hanoi, Vietnam;Respiratory Department, National Hospital of Pediatrics, No. 18, Alley 897, La Thanh Street, Dong Da District, Hanoi, Vietnam

关键词: Children;    Ganciclovir;    Cytomegalovirus-associated pneumonia;   

Others  :  1145836
DOI  :  10.1186/1471-2334-13-424

 received in 2013-01-20, accepted in 2013-08-21,  发布年份 2013

【 摘 要 】

Background

This study aimed to evaluate the effectiveness of gancyclovir (GCV) treatment for severe cytomegalovirus (CMV)-associated pneumonia in immunocompetent children.

Method

We enrolled patients with CMV-associated severe pneumonia admitted to the Vietnam National Hospital of Pediatrics, Hanoi, Vietnam, from January 2010 to December 2011. On admission, though respiratory bacteria and viruses were not detected in tracheal aspirates, more than 5 × 10³ copies/mL of CMV-DNA were detected in both tracheal aspirates and in blood plasma. GCV was given intravenously at a dose of 10 mg/kg/24 h for a duration of 14 days at most. The dose was then reduced to 5 mg/kg/24 h until CMV-DNA was not detected in plasma. The main study variables included clinical symptoms, complete blood count, hepatic and renal function, chest X-ray, CMV viral load, duration of GCV treatment and outcome.

Results

Forty-three patients were enrolled in the study. The median age of patients was 57 (interquartile range [IQR] 45–85) days. Clinical and laboratory findings included anemia (67.4%), leukocytosis (90.7%), hepatosplenomegaly (60.5%), elevated liver enzymes (74.4%), decreased ratio of CD4: CD8-positive T lymphocytes (69.4%), and decreased serum IgG concentration (25.7%). The median duration of GCV treatment was 12 days (IQR 7-21). Thirty-seven patients (86.0%) showed normal chest X-rays at the end of treatment. One infant died (2.3%); the other children (97.7%) were discharged in good condition. There was no severe toxicity associated with GCV treatment.

Conclusion

GCV is safe and effective for the treatment of severe CMV-associated pneumonia in children.

【 授权许可】

   
2013 Doan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zampoli M, Morrow MB, Hsiao NY, et al.: Prevalence and outcome of cytomegalovirus-associated pneumonia in relation to Human immunodeficiency Virus infection. Pediatr Infect Dis J 2011, 30:413-417.
• [2]Capulong G, Mendoza MT, Chavez J: Cytomegalovirus Pneumonia in Renal Transplant Patients. Phil J Microbiol Infect Dis 1998, 30:109-112.
• [3]Tamm M, Traenkle P, Grilli B, et al.: Pulmonary cytomegalovirus infection in Immunocompromised Patients. Chest 2001, 119:834-838.
• [4]Eddleston M, Peacock S, Juniper M, et al.: Severe Cytomegalovirus Infection in Immunocompetent Patients. Clinical Infectious Disease 1997, 24:52-56.
• [5]Rafailidis PI, Mourtzoukou EG, Varbobitis IC, et al.: Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008, 5:47. BioMed Central Full Text
• [6]Cunha BA, Pherez F, Walls N: Severe cytomegalovirus (CMV) community acquired pneumonia (CAP) in a nonimmunocompromised host. Lung 2009, 38:243-248.
• [7]Avila-Agüero ML, Paris MM, Alfaro I, et al.: Ganciclovir therapy in cytomegalovirus (CMV) infection in immunocompetent pediatric patients. Int J Infect Dis 2003, 7:278-281.
• [8]Siret D, David V: Treatment of cytomegalovirus pneumonia with ganciclovir in an immunocompetent infant. Arch Pediatr 2002, 9:499-502.
• [9]WHO: The management of acute respiratory infection in children. Geneva, Switzerland: Practical guidelines for outpatient care; 2006.
• [10]Hadaya K, Wunderli W, Deffernez C, et al.: Monitoring of Cytomegalovirus Infection in Solid-Organ Transplant Recipients by Ultrasensitive Plasma PCR assay. J Clin Microbiol 2003, 41:3757-3764.
• [11][http://www.mayomedicallaboratories.com/test/pediatric/referencevalue] webcitePediatric Test Reference Values.
• [12]Jollift CR, Cost KM, Stivrins PC, et al.: Reference Intervals for Serum IgG, IgA, IgM, C3, and C4 as Determined by Rate Nephelometry. Clin Chem 1982, 28:126-128.
• [13]Ducroux A, Cherid S, Benachi A, et al.: Evaluation of New Commercial Real-Time PCR Quantification Assay for Prenatal Diagnosis of Cytomegalovirus Congenital Infection. J Clin Microbiol 2008, 46:2078-2080.
• [14]Pass RF: Cytomegalovirus. Philadelphia: Churchill Livingstone; 2008:1029-1035. [Third edn. Principle and Practice of Pediatric Infectious Diseases]
• [15]Numazaki K, Chiba S: Human cytomegalovirus infections in premature infants by breastfeeding. Afri J of Biot 2005, 4:867-872.
• [16]Jim WT, Shu SH, Chiu NC, et al.: High Cytomegalovirus Load and Prolonged Virus Excretion in Breast Milk Increase Risk for Viral Acquisition by Very Low Birth Weight Infants. Pediatr Infect Dis J 2009, 28:891-894.
• [17]Kim EA, Lee KS, Primack SL, et al.: Viral Pneumonias in Adults: Radiologic and Pathologic Findings. RadioGraphics 2002, 22:137-149.
• [18]Chemaly RF, Yen-Lieberman B, Castilla EA, Reilly A, Arrigain S, et al.: Correlation between Viral Loads of Cytomegalovirus in Blood and Bronchoalveolar Lavage Specimens from Lung Transplant Recipients Determined by Histology and Immunohistochemistry. J Clin Microbiol 2004, 42:2168-2172.
• [19]Kimberlin DW: Antiviral Therapy for Cytomegalovirus Infections in Pediatric Patients. Seminars in Pediatr Infect Dis J 2006, 13:22-30.
• [20]Biron KK: Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71:154-163.